Satish Nagaraj

[Enzene Biosciences Ltd. @enzenebio]

Heading to #BIO2024 next week? Don’t miss the chance to connect with our BD team at booth #5857! Whether you’re looking for innovative solutions, potential collaborations, or expert insights in #biologics, we’re here to help.

Book a meeting now 👉https://t.co/ZOkuA5awqQ

#CDMO

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio is all geared up to engage in insightful discussions about our biosimilar portfolio's potential for global expansion. Join our delegates at Bio-Europe 2024 and explore avenues for collaborating with us. See you in Spain!

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio's state-of-the-art continuous manufacturing technology, EnzeneX™ was recognized as a finalist at the Aegis Graham Bell Award's this week, for its exceptional contribution to the advancement of biotechnology.
Congratulations Team Enzene!

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio would like to thank all of you for being a part of our incredible journey so far. Here's wishing you a festive holiday season and a prosperous new year!

[Enzene Biosciences Ltd. @enzenebio]

Launching Continuous Manufacturing in the US for Biologics!

Follow the link below to learn more about @enzenebio 's expansion to the U.S. and our commitment to supporting smaller players in the biotech industry
https://t.co/kqbdzJDOAa

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio is looking forward to connecting with you at this year’s BioEurope to discuss potential opportunities for our biosimilars across borders.
https://t.co/3NrBHxD9oP

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio proudly announces the approval of Enzene's Ranibizumab - a Recombinant F(ab) poised to democratize therapy access for millions of Age-related macular degeneration (AMD) patients across India.
https://t.co/SLoy8UQxvW

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio is looking forward to its presence at CPHI worldwide next week. Our team is excited to network with industry experts, share insights into Enzene’s vision and explore potential collaborations for our global biosimilar pipeline.
https://t.co/RDts1ZnbLM

[Enzene Biosciences Ltd. @enzenebio]

We’re seeking dynamic alliances with like-minded organizations and innovators from around the world for our biosimilar – Denosumab. We invite you to connect with us at the event this year and explore potential opportunities!
https://t.co/SHZ3vR2ah2

[Enzene Biosciences Ltd. @enzenebio]

“Besides reducing costs, a platform, where the product is removed continuously, ‘works beautifully’ for tough-to-make biologics such as human-engineered antibodies”, says @enzenebio CEO, Himanshu Gadgil.

https://t.co/eALdgwKDqB

[Enzene Biosciences Ltd. @enzenebio]

If you're attending BioJapan 2023, we'd love to meet you in person! @enzenebio is looking forward to discussing our pipeline biosimilars – now open for global expansion.
https://t.co/QSWCK8Fd6p

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio is a sponsor at this year’s Festival of Biologics. Our delegates are excited to showcase EnzeneX™, our continuous manufacturing platform, and eager to discuss how EnzeneX™ would be able to help and solve challenges you may be facing.
https://t.co/miCcrR0CdR

[Enzene Biosciences Ltd. @enzenebio]

In partnership with Sartorius, our colleagues Harshita Londhe and Abijar Bhori, have co-authored an insightful application note titled: Intensifying a mAb Polishing Platform — Targeting Time, Cost, and Space Efficiency.
https://t.co/KyeNnZSemx

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio takes home not one, but two prestigious awards at the Asia Pacific Biologics CMO awards!
“Best Biologics CMO in South Asia”
“Best Biologics CMO – Analytical Services”
https://t.co/ZlXKK7R8Et

[Enzene Biosciences Ltd. @enzenebio]

Our CEO, Dr. Himanshu Gadgil, is excited to showcase the progress we’ve achieved with our commercially validated, seamlessly integrated continuous manufacturing platform – EnzeneX.
Here is a link to more details on this - https://t.co/1pSaHdHweX

[Enzene Biosciences Ltd. @enzenebio]

At Biopharm America, @enzenebio will be exploring partnerships for 5 of our products – Denosumab, Teriparatide, Tocilizumab, Romiplostim and Liraglutide for various territories. Let's talk! Please reach out to us at [email protected].
https://t.co/ta8GvZtOBr

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio will be speaking and exhibiting at this year’s Bioprocessing International conference. Meet with our CEO (Himanshu Gadgil), CCO (Lourdes Gonzalez-Novo, MBA) and Global Commercial Operations team at the conference.
https://t.co/zVmGUHxsma

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio is looking forward to connecting with fellow pharma professionals at this year’s BioPharm America and discussing our expanding biosimilar pipeline for licensing opportunities through innovative collaborations.
https://t.co/0z6iviSD1O

[Enzene Biosciences Ltd. @enzenebio]

Enabling local manufacturing with access to our cutting-edge continuous manufacturing platform, EnzeneX, for our US-based partners is the reason behind Enzene’s upcoming facility in NJ.
See our participation at BPS here https://t.co/ABx4Hi5FoS

[Enzene Biosciences Ltd. @enzenebio]

@enzenebio is participating in The Bioprocessing Summit, taking place in Boston from August 14 - 17. Stay tuned for more updates on our presence at the BPS. See you in Boston! https://t.co/cqGVKOecLe